ClinicalTrials.gg
CompletedNCT00259272Updated Jun 24, 2009Results posted

Validation of Multidimensional Assessment of THYmic States (MATHYS): A Study in a Population of Bipolar Patients Treated With Olanzapine

A Phase 3 interventional study of olanzapine in Bipolar Disorder I or II, sponsored by Eli Lilly and Company. Completed at 16 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-06-24.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
141
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing olanzapine in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Olanzapine · Bipolar Disorder.

Enrollment
11th of 28
141 · median 120
Started
2005
with 3 others
Phase 3
7 of 28
none open now
Registered
16th of 28
by date
Lead sponsor
13 of 28
Eli Lilly and Company

Among the 28 studies testing olanzapine in Bipolar Disorder, this one is the 11th largest by enrollment, is one of 4 that started in 2005, is one of 7 in phase 3, and was the 16th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

None of the 28 studies testing olanzapine in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →

About olanzapine

Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies testing olanzapine in Bipolar Disorder as a file.
02

Study summary

A non randomized study to validate the MATHYS Scale in a population of in and outpatients greater than or equal to 18 years of age, suffering from Bipolar Disorder I or II, and treated with olanzapine.

03

Conditions studied

  • Bipolar Disorder I or II

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must meet , Fourth Edition, Text Revision (DSM-IV-TR) disease diagnostic criteria for Bipolar Disorder

    • currently or most recently in a Manic Episode (Single Manic Episode or Most Recent Episode Manic) or
    • currently or most recently in a Hypomanic Episode or
    • currently or most recently in a Mixed Episode or
    • currently or most recently in a Major Depressive Episode
    • and confirmed by the module D of the SCID (Semi-Structured Interview).
  2. Patients must be more than 18 of age at Visit 0.

Exclusion criteria

Exclusion Criteria:

  1. A valid current or lifetime Axis I or II diagnosis which could interfere, at the investigator's opinion, with the evaluation.
  2. Patients on antidepressant or mood stabilizer therapy one week (four weeks with fluoxetine) prior to Visit 1, with the exception of mood stabilizer therapy considered in the opinion of the investigator as an efficient treatment for at least one year prior to the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
141 participants (actual)

Study arms

  • Experimental
    A

    Drug: olanzapine

Interventions

  • 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks.

    Also known as: LY170053, Velotab, Zydis

06

What researchers measure

Primary outcomes

  1. Mean Changes From Baseline to 6 Week and 24 Week Endpoints in the Multidimensional Assessment of THYmic States Scale (MATHYS) Total Score

    A visual analogic scale consisting of 20 items. Item scores vary from 0 (inhibition of the state evaluated by the item) to 10 (excitation for the evaluated state), except for items 5 to 10 and 17 and 18 which are inversed and are consequently to be reversed before the analysis. Total score is sum of the 20 items and can vary from 0 to 200.

    Time frame: Baseline, 6 Weeks, 24 weeks

  2. Baseline MATHYS Assessment - Principal Component Analysis and Orthogonal Transformation Matrix

    This analysis indicates whether the total score is correct and provides enough information, or if subscores need to be calculated. Eigen value, proportion and cumulative are statistical parameters from the Principal Component Analysis, given for each factor.

    Time frame: Baseline

Secondary outcomes

  1. Mean Change From Baseline to 6 Week and 24 Week Endpoints in the Hamilton 17-Items Depression Scale (HAMD-17) Total Score

    The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (not at all depressed) to 52 (severely depressed).

    Time frame: Baseline, 6 Weeks, 24 Weeks

  2. Mean Change From Baseline to 6 Week and 24 Week Endpoints in the Hamilton Anxiety Scale (HAMA) Total Score

    The 14-item HAMA assesses the severity of anxiety. The investigator talked to the patient about their symptoms over the previous week before the study visit. Each item was scored using a 5-point scale, i.e. 0 = absent to 4 = severe. The total score of HAMA-14 may range from 0 (not present) to 56 (very severe).

    Time frame: Baseline, 6 Weeks, 24 Weeks

  3. Mean Change From Baseline to 6 Week and 24 Week Endpoints in the Young Mania Rating Scale (YMRS) Total Score

    The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

    Time frame: Baseline, 6 Weeks, 24 Weeks

  4. Mean Change From Baseline to 24 Week Endpoint in Glycaemia Levels (Glucose Fasting Levels)

    Time frame: baseline and 24 weeks

  5. Increases and Decreases in Fasting Glucose Levels

    Time frame: over 24 weeks

  6. Mean Change From Baseline to 24 Week Endpoint in Lipids

    Baseline, change from baseline, and percent change for the following lipids are presented: Total Cholesterol (TC), High Density Lipoproteins (HDL), Low Density Lipoproteins (LDL), and Triglycerides (TG).

    Time frame: Baseline and 24 Weeks

  7. Increases and Decreases in Lipid Levels

    Time frame: over 24 weeks

  8. Mean Change From Baseline to 24 Week Endpoint in Weight

    Time frame: Baseline and 24 weeks

  9. Weight Gain Compared to Baseline

    Weight gain at anytime more than 7%-15% or 25% of body weight compared to baseline

    Time frame: over 24 weeks

  10. Wellness Interventional Program for Weight Gain Management in Patients (for Those Who Gain at Anytime More Than 7% of Body Weight, Compared to Baseline)

    Time frame: 24 weeks

  11. MATHYS Total Score at Baseline - According to Thymic Reactivity Assessment

    A visual analogic scale consisting of 20 items. Items scores vary from 0 (inhibition of the state evaluated by the item) to 10 (excitation for the evaluated state), except for items 5 to 10 and 17 and 18, which are inversed and are consequently to be reversed before the analysis. Total score is sum of the 20 items and can vary from 0 to 200.

    Time frame: Baseline

  12. Change From Baseline to 6 Week and 24 Week Endpoints in HAMA Total Scores - According to Thymic Reactivity Assessment

    The 14-item HAMA assesses the severity of anxiety. The investigator talked to the patient about their symptoms over the previous week before the study visit. Each item was scored using a 5-point scale, i.e. 0 = absent to 4 = severe. The total score of HAMA-14 may range from 0 (not present) to 56 (very severe).

    Time frame: Baseline, 6 Weeks, 24 Weeks

  13. Change From Baseline to 6 Week and 24 Week Endpoints in HAMD-17 Total Scores - According to Thymic Reactivity Assessment

    The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (not at all depressed) to 52 (severely depressed).

    Time frame: Baseline, 6 Weeks, 24 Weeks

  14. Change From Baseline to 6 Week and 24 Week Endpoints in YMRS Total Scores - According to Thymic Reactivity Assessment

    The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

    Time frame: Baseline, 6 Weeks, 24 Weeks

  15. Emotional Reactivity With the Physiological Measure of Heart Rate

    to assess emotional reactivity with the physiological measure of heart rate, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients

    Time frame: 12 weeks

  16. Emotional Reactivity With the Physiological Measure of Skin Conductance

    To assess emotional reactivity with the physiological measure of skin conductance, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients.

    Time frame: 12 weeks

  17. Emotional Reactivity With the Physiological Measure of Startle Reflex Response - Latency of Blink

    To assess emotional reactivity with the physiological measure of startle reflex response by measuring the latency of the blink, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients.

    Time frame: 12 weeks

  18. Emotional Reactivity With the Physiological Measure of Startle Reflex Response - Amplitude of Blink

    To assess emotional reactivity with the physiological measure of startle reflex response - by measuring the amplitude of the blink, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients.

    Time frame: 12 weeks

07

Results

Posted Jun 24, 2009
Limitations and caveats
Fewer patients than planned were enrolled in the study. Not all the analyses (Principal Component Analysis, scree plot to define the structure) could be provided due to the specific formatting of the clinicaltrials.gov databank.

Participant flow

Participant flow — Overall Study
MilestoneManic EpisodeHypomanic EpisodeMixed EpisodeDepressive Episode
Started36312648
Completed21242127
Not completed157521
Withdrew: Adverse event2103
Withdrew: Lack of efficacy5126
Withdrew: Physician decision1213
Withdrew: Protocol violation2001
Withdrew: Sponsor decision0100
Withdrew: Withdrawal by subject4227
Withdrew: Lost to follow-up1001

Outcome measures

PrimaryMean Changes From Baseline to 6 Week and 24 Week Endpoints in the Multidimensional Assessment of THYmic States Scale (MATHYS) Total Score

A visual analogic scale consisting of 20 items. Item scores vary from 0 (inhibition of the state evaluated by the item) to 10 (excitation for the evaluated state), except for items 5 to 10 and 17 and 18 which are inversed and are consequently to be reversed before the analysis. Total score is sum of the 20 items and can vary from 0 to 200.

Time frame:
Baseline, 6 Weeks, 24 weeks
Reported as:
Mean · units on a scale
Mean Changes From Baseline to 6 Week and 24 Week Endpoints in the Multidimensional Assessment of THYmic States Scale (MATHYS) Total Score
units on a scaleManic EpisodeHypomanic EpisodeMixed EpisodeDepressive Episode
Baseline (n=34, 31, 25, 48)140.55 ± 22.18136.52 ± 22.45116.74 ± 21.3076.88 ± 22.91
6 Week Endpoint (n=31, 31, 25, 44)115.37 ± 23.09105.15 ± 23.10101.58 ± 22.5593.41 ± 23.71
Change from 6 Week Endpoint (n=30, 31, 24, 44)-22.91 ± 28.70-31.37 ± 30.46-13.32 ± 26.3717.17 ± 26.62
24 Week Endpoint (n=35, 31, 26, 47)115.15 ± 24.84103.16 ± 23.0391.56 ± 25.1994.58 ± 27.09
Change from 24 Week Endpoint (n=34, 31, 25, 47)-24.67 ± 24.83-33.36 ± 33.61-26.08 ± 40.5117.04 ± 31.81
SecondaryMean Change From Baseline to 6 Week and 24 Week Endpoints in the Hamilton 17-Items Depression Scale (HAMD-17) Total Score

The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (not at all depressed) to 52 (severely depressed).

Time frame:
Baseline, 6 Weeks, 24 Weeks
Reported as:
Mean · units on a scale
Mean Change From Baseline to 6 Week and 24 Week Endpoints in the Hamilton 17-Items Depression Scale (HAMD-17) Total Score
units on a scaleManic EpisodeHypomanic EpisodeMixed EpisodeDepressive Episode
Baseline (n=35, 30, 26, 48)6.46 ± 4.868.43 ± 5.3312.65 ± 4.8316.06 ± 7.19
Change from 6 Week Endpoint (n=29, 29, 25, 45)-1.79 ± 4.59-3.10 ± 4.59-5.60 ± 6.60-8.51 ± 6.22
Change from 24 Week Endpoint (n=34, 30, 26, 47)-1.74 ± 5.02-3.20 ± 6.40-5.50 ± 6.72-7.96 ± 7.18
SecondaryMean Change From Baseline to 6 Week and 24 Week Endpoints in the Hamilton Anxiety Scale (HAMA) Total Score

The 14-item HAMA assesses the severity of anxiety. The investigator talked to the patient about their symptoms over the previous week before the study visit. Each item was scored using a 5-point scale, i.e. 0 = absent to 4 = severe. The total score of HAMA-14 may range from 0 (not present) to 56 (very severe).

Time frame:
Baseline, 6 Weeks, 24 Weeks
Reported as:
Mean · units on a scale
Mean Change From Baseline to 6 Week and 24 Week Endpoints in the Hamilton Anxiety Scale (HAMA) Total Score
units on a scaleManic EpisodeHypomanic EpisodeMixed EpisodeDepressive Episode
Baseline (n=36, 31, 26, 48)7.78 ± 6.2911.94 ± 7.7315.46 ± 7.1715.08 ± 7.35
Change from 6 Week Endpoint (n=31, 31, 25, 45)-2.68 ± 4.85-5.48 ± 5.89-7.32 ± 6.31-6.76 ± 6.61
Change from 24 Week Endpoint (n=35, 31, 26, 47)-2.26 ± 4.80-5.65 ± 7.36-7.62 ± 7.87-6.83 ± 7.19
SecondaryMean Change From Baseline to 6 Week and 24 Week Endpoints in the Young Mania Rating Scale (YMRS) Total Score

The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

Time frame:
Baseline, 6 Weeks, 24 Weeks
Reported as:
Mean · units on a scale
Mean Change From Baseline to 6 Week and 24 Week Endpoints in the Young Mania Rating Scale (YMRS) Total Score
units on a scaleManic EpisodeHypomanic EpisodeMixed EpisodeDepressive Episode
Baseline (n=36, 31, 25, 46)24.50 ± 10.3417.84 ± 4.8812.96 ± 7.692.78 ± 3.64
Change from 6 Week Endpoint (n=31, 31, 24, 43)-13.65 ± 9.38-13.13 ± 6.02-9.67 ± 7.91-0.86 ± 3.54
Change from 24 Week Endpoint (n=35, 31, 25, 45)-14.00 ± 10.94-14.45 ± 7.36-10.60 ± 7.95-0.82 ± 3.24
SecondaryMean Change From Baseline to 24 Week Endpoint in Glycaemia Levels (Glucose Fasting Levels)
Time frame:
baseline and 24 weeks
Reported as:
Mean · milligrams per deciliter
Mean Change From Baseline to 24 Week Endpoint in Glycaemia Levels (Glucose Fasting Levels)
milligrams per deciliterManic EpisodeHypomanic EpisodeMixed EpisodeDepressive Episode
Baseline (n=33, 30, 23, 47)89.27 ± 16.3185.99 ± 11.3385.94 ± 12.5888.52 ± 13.95
Change from 24 Week Endpoint (n=26, 28, 23, 40)-3.07 ± 16.154.65 ± 15.323.89 ± 9.627.31 ± 30.42
SecondaryIncreases and Decreases in Fasting Glucose Levels
Time frame:
over 24 weeks
Reported as:
Number · participants
Increases and Decreases in Fasting Glucose Levels
participantsManic EpisodeHypomanic EpisodeMixed EpisodeDepressive Episode
At Least One Increase in Fasting Glucose (FG)59310
At Least One Decrease in FG48111
At Least One Increase/Decrease in FG710315
Patients Who Increase and Decrease During Study2716
SecondaryMean Change From Baseline to 24 Week Endpoint in Lipids

Baseline, change from baseline, and percent change for the following lipids are presented: Total Cholesterol (TC), High Density Lipoproteins (HDL), Low Density Lipoproteins (LDL), and Triglycerides (TG).

Time frame:
Baseline and 24 Weeks
Reported as:
Mean · milligrams per deciliter
Mean Change From Baseline to 24 Week Endpoint in Lipids
milligrams per deciliterManic EpisodeHypomanic EpisodeMixed EpisodeDepressive Episode
TC Baseline (n=33, 30, 24, 46)182.88 ± 41.88191.55 ± 42.49210.51 ± 50.78203.77 ± 44.66
Change in TC from 24 Week Endpoint (n=26,28,23,41)23.64 ± 33.952.26 ± 27.257.03 ± 30.774.41 ± 50.69
Percent Change in TC (n=26, 28, 23, 41)14.96 ± 19.573.10 ± 13.834.41 ± 16.974.68 ± 23.67
HDL Baseline (n=33, 30, 23, 46)50.21 ± 14.6556.87 ± 16.7757.46 ± 19.1350.78 ± 13.35
Change in HDL from Endpoint (n=26, 28, 22, 41)1.24 ± 13.321.57 ± 13.14-0.45 ± 16.273.25 ± 12.72
Percent Change in HDL (n=26, 28, 22, 41)6.04 ± 26.436.17 ± 26.063.78 ± 26.128.87 ± 23.97
LDL Baseline (n=34, 30, 23, 46)112.76 ± 39.81112.16 ± 31.37129.70 ± 44.64128.81 ± 39.26
Change in LDL from Endpoint (n=27, 27, 22, 41)14.22 ± 41.051.28 ± 36.649.46 ± 32.04-1.19 ± 42.24
Percent Change in LDL (n=27, 27, 22, 41)20.54 ± 33.945.15 ± 33.0511.37 ± 28.573.41 ± 32.28
TG Baseline (n=35, 30, 23, 46)115.81 ± 43.15110.66 ± 89.64131.37 ± 71.65120.15 ± 66.63
Change in TG from 24 Week Endpoint (n=27,28,22,41)8.37 ± 66.5025.86 ± 90.32-1.16 ± 49.0613.85 ± 67.59
Percent Change in TG (n=27, 28, 22, 41)20.65 ± 72.4240.06 ± 74.564.10 ± 36.5925.95 ± 60.73
SecondaryIncreases and Decreases in Lipid Levels
Time frame:
over 24 weeks
Reported as:
Number · participants
Increases and Decreases in Lipid Levels
participantsManic EpisodeHypomanic EpisodeMixed EpisodeDepressive Episode
At Least One Increase for Total Cholesterol (TC)1871120
At Least One Decrease for TC1191016
At Least One Increase/Decrease for TC19121426
Patients Who Increase & Decrease in TC104710
≥1 Increase for High Density Lipoprotein (HDL)85611
At Least One Decrease for HDL4658
At Least One Increase/Decrease for HDL98712
Patients Who Increase & Decrease in HDL3347
≥1 Increase for Low Density Lipoprotein (LDL)1581117
At Least One Decrease for LDL87717
At Least One Increase/Decrease for LDL17121225
Patients Who Increase & Decrease in LDL6369
At Least One Increase for Triglycerides (TG)117611
At Least One Decrease for TG127713
At Least One Increase/Decrease for TG1511816
Patients Who Increase & Decrease in TG8358
SecondaryMean Change From Baseline to 24 Week Endpoint in Weight
Time frame:
Baseline and 24 weeks
Reported as:
Mean · kilograms
Mean Change From Baseline to 24 Week Endpoint in Weight
kilogramsManic EpisodeHypomanic EpisodeMixed EpisodeDepressive Episode
Mean Change From Baseline to 24 Week Endpoint in Weight1.37 ± 2.981.91 ± 3.441.78 ± 4.432.15 ± 2.60
SecondaryWeight Gain Compared to Baseline

Weight gain at anytime more than 7%-15% or 25% of body weight compared to baseline

Time frame:
over 24 weeks
Reported as:
Number · participants
Weight Gain Compared to Baseline
participantsManic EpisodeHypomanic EpisodeMixed EpisodeDepressive Episode
No Significant Gain30 ± 2.9826 ± 3.4418 ± 4.4342 ± 2.60
>25%0000
>15%1210
>7%5375
Missing Data0001
SecondaryWellness Interventional Program for Weight Gain Management in Patients (for Those Who Gain at Anytime More Than 7% of Body Weight, Compared to Baseline)
Time frame:
24 weeks
Reported as:
Number · participants
Wellness Interventional Program for Weight Gain Management in Patients (for Those Who Gain at Anytime More Than 7% of Body Weight, Compared to Baseline)
participantsWeight Gain Subgroup
Advised to Consult Dietician - No8
Advised to Consult Dietician - Yes16
Performed a Wellness Program - No6
Performed a Wellness Program - Yes10
Number of Wellnes Program Consults - 15
Number of Wellnes Program Consults - 22
Number of Wellnes Program Consults - 33
Patients Losing Weight After Consultation8
Patients Gaining Weight After Consultation8
Patients with Stable Weight After Consultation0
SecondaryMATHYS Total Score at Baseline - According to Thymic Reactivity Assessment

A visual analogic scale consisting of 20 items. Items scores vary from 0 (inhibition of the state evaluated by the item) to 10 (excitation for the evaluated state), except for items 5 to 10 and 17 and 18, which are inversed and are consequently to be reversed before the analysis. Total score is sum of the 20 items and can vary from 0 to 200.

Time frame:
Baseline
Reported as:
Mean · units on a scale
MATHYS Total Score at Baseline - According to Thymic Reactivity Assessment
units on a scaleThymic Hypo-ReactiveThymic Hyper-ReactivityNeither
MATHYS Total Score at Baseline - According to Thymic Reactivity Assessment81.24 ± 30.81122.49 ± 32.01117.26 ± 26.41
SecondaryChange From Baseline to 6 Week and 24 Week Endpoints in HAMA Total Scores - According to Thymic Reactivity Assessment

The 14-item HAMA assesses the severity of anxiety. The investigator talked to the patient about their symptoms over the previous week before the study visit. Each item was scored using a 5-point scale, i.e. 0 = absent to 4 = severe. The total score of HAMA-14 may range from 0 (not present) to 56 (very severe).

Time frame:
Baseline, 6 Weeks, 24 Weeks
Reported as:
Mean · units on a scale
Change From Baseline to 6 Week and 24 Week Endpoints in HAMA Total Scores - According to Thymic Reactivity Assessment
units on a scaleThymic Hypo-ReactivityThymic Hyper-ReactivityNeither
Baseline (n=30, 101, 10)12.87 ± 7.0912.63 ± 7.9511.40 ± 7.95
Change from 6 Week Endpoint (n=29, 93, 10)-4.93 ± 5.62-5.96 ± 6.56-4.30 ± 3.95
Change from 24 Week Endpoint (n=30, 99, 10)-4.83 ± 5.94-5.65 ± 7.39-6.90 ± 7.43
SecondaryChange From Baseline to 6 Week and 24 Week Endpoints in HAMD-17 Total Scores - According to Thymic Reactivity Assessment

The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (not at all depressed) to 52 (severely depressed).

Time frame:
Baseline, 6 Weeks, 24 Weeks
Reported as:
Mean · units on a scale
Change From Baseline to 6 Week and 24 Week Endpoints in HAMD-17 Total Scores - According to Thymic Reactivity Assessment
units on a scaleThymic Hypo-ReactivityThymic Hyper-ReactivityNeither
Baseline (n=29, 100, 10)14.48 ± 7.0210.64 ± 6.859.50 ± 7.01
Change from 6 Week Endpoint (n=28, 90, 10)-6.61 ± 5.02-4.89 ± 6.62-4.00 ± 5.12
Change from 24 Week Endpoint (n=28, 98, 10)-6.48 ± 4.32-4.55 ± 7.58-3.80 ± 4.85
SecondaryChange From Baseline to 6 Week and 24 Week Endpoints in YMRS Total Scores - According to Thymic Reactivity Assessment

The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

Time frame:
Baseline, 6 Weeks, 24 Weeks
Reported as:
Mean · units on a scale
Change From Baseline to 6 Week and 24 Week Endpoints in YMRS Total Scores - According to Thymic Reactivity Assessment
units on a scaleThymic Hypo-ReactivityThymic Hyper-ReactivityNeither
Baseline (n=27, 101, 10)4.48 ± 7.9916.50 ± 10.6510.00 ± 7.24
Change from 6 Week Endpoint (n=26, 93, 10)-2.38 ± 7.90-10.45 ± 8.46-6.50 ± 4.70
Change from 24 Week Endpoint (n=27, 99, 10)-1.70 ± 5.19-11.29 ± 9.89-7.60 ± 5.52
SecondaryEmotional Reactivity With the Physiological Measure of Heart Rate

to assess emotional reactivity with the physiological measure of heart rate, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients

Time frame:
12 weeks
Reported as:
Mean · beats per minute

No measurements were reported for this outcome.

SecondaryEmotional Reactivity With the Physiological Measure of Skin Conductance

To assess emotional reactivity with the physiological measure of skin conductance, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients.

Time frame:
12 weeks
Reported as:
Mean · microvolts

No measurements were reported for this outcome.

SecondaryEmotional Reactivity With the Physiological Measure of Startle Reflex Response - Latency of Blink

To assess emotional reactivity with the physiological measure of startle reflex response by measuring the latency of the blink, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients.

Time frame:
12 weeks
Reported as:
Mean · seconds

No measurements were reported for this outcome.

SecondaryEmotional Reactivity With the Physiological Measure of Startle Reflex Response - Amplitude of Blink

To assess emotional reactivity with the physiological measure of startle reflex response - by measuring the amplitude of the blink, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients.

Time frame:
12 weeks
Reported as:
Mean · microvolts

No measurements were reported for this outcome.

PrimaryBaseline MATHYS Assessment - Principal Component Analysis and Orthogonal Transformation Matrix

This analysis indicates whether the total score is correct and provides enough information, or if subscores need to be calculated. Eigen value, proportion and cumulative are statistical parameters from the Principal Component Analysis, given for each factor.

Time frame:
Baseline
Reported as:
Number · value
Baseline MATHYS Assessment - Principal Component Analysis and Orthogonal Transformation Matrix
valueEigen ValueProportionCumulative
Factor 18.770.43830.4383
Factor 22.010.10060.5389
Factor 31.190.05940.5984
Factor 41.0420.05210.6505
Factor 50.980.04900.6995
Factor 60.790.03970.7392
Factor 70.690.03470.7739
Factor 80.640.03220.8061
Factor 90.560.02800.8341
Factor 100.540.02680.8608
Factor 110.450.02270.8836
Factor 120.440.02190.9055
Factor 130.370.01860.9241
Factor 140.340.01710.9412
Factor 150.280.01390.9551
Factor 160.260.01310.9682
Factor 170.200.01000.9782
Factor 180.180.00910.9873
Factor 190.140.00710.9944
Factor 200.110.00561.0000

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olanzapine———
Most frequent serious events
Most frequent serious events
EventOlanzapine
Bipolar I disorderPsychiatric disorders5/141
DepressionPsychiatric disorders4/141
Gastric ulcerGastrointestinal disorders1/141
CholecystitisHepatobiliary disorders1/141
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/141
AlcoholismPsychiatric disorders1/141
AnxietyPsychiatric disorders1/141
Suicide attemptPsychiatric disorders1/141
ArteritisVascular disorders1/141
Most frequent other events
Showing 10 of 52
Most frequent other events
EventOlanzapine
Dry mouthGastrointestinal disorders8/141
ConstipationGastrointestinal disorders7/141
SomnolenceNervous system disorders7/141
TremorNervous system disorders7/141
AstheniaGeneral disorders3/141
Weight increasedInvestigations3/141
Vision blurredEye disorders2/141
DiarrhoeaGastrointestinal disorders2/141
VomitingGastrointestinal disorders2/141
Gamma-glutamyltransferase increasedInvestigations2/141

Baseline characteristics

Age Continuous
Age Continuous(years)Manic EpisodeHypomanic EpisodeMixed EpisodeDepressive EpisodeTotal
Mean46.39 ± 15.3245.81 ± 11.6846.62 ± 12.8744.35 ± 11.9845.61 ± 12.91
Sex: Female, Male
Sex: Female, Male(Participants)Manic EpisodeHypomanic EpisodeMixed EpisodeDepressive EpisodeTotal
Female1921152580
Male1710112361
Region of Enrollment
Region of Enrollment(participants)Manic EpisodeHypomanic EpisodeMixed EpisodeDepressive EpisodeTotal
France36312648141
Diagnostic Summary
Diagnostic Summary(participants)Manic EpisodeHypomanic EpisodeMixed EpisodeDepressive EpisodeTotal
Bipolar Disorder I36142631107
Bipolar Disorder II - Hypomanic0171018
Bipolar Disorder II - Depressed0011718
Number of Lifetime Suicide Attempts
Number of Lifetime Suicide Attempts(participants)Manic EpisodeHypomanic EpisodeMixed EpisodeDepressive EpisodeTotal
Missing Data23128
02423152890
1836522
2203813
401023
500022
601001
1000112
Participants with at Least One Episode of Depression
Participants with at Least One Episode of Depression(participants)Manic EpisodeHypomanic EpisodeMixed EpisodeDepressive EpisodeTotal
Missing Data00101
No624012
Yes30292148128
Participants with at Least One Episode of Hypomania
Participants with at Least One Episode of Hypomania(participants)Manic EpisodeHypomanic EpisodeMixed EpisodeDepressive EpisodeTotal
Missing Data20316
No301142570
Yes43092265
Participants with at Least One Episode of Mania
Participants with at Least One Episode of Mania(participants)Manic EpisodeHypomanic EpisodeMixed EpisodeDepressive EpisodeTotal
Missing Data03104
No014112348
Yes3614142589

10 further baseline measures are reported on the registry.

08

Study locations

16 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Andilly, 95580, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bordeaux, 33076, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cornebarrieu, 31700, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Creteil, 94010, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    La Rochelle, 17000, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    La Seyne Sur Mer, 83500, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lyon, 69322, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Marseille, 13385, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montpellier, 34094, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nimes, 30029, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orvault, 44700, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paris, 75019, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pin Balma, 31130, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Plaisir, 78373, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Poitiers, 86021, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toulouse, 31300, France
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2005, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2005
First posted
Nov 29, 2005
Start
Nov 2005
Primary completionActual
May 2008
CompletionActual
May 2008
Results first posted
Jun 24, 2009
Last update
Jun 24, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00259272
First posted
Nov 29, 2005
Start date
Nov 2005
Primary completion
May 2008
Completion
May 2008
Results posted
Jun 24, 2009
Last update
Jun 24, 2009

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT-5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion